A Phase II Study of Neoadjuvant Chemotherapy With Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
In our previous phase II study of neoadjuvant docetaxel, capecitabine and cisplatin
chemotherapy, patients with unresectable gastric cancer because of invasion to adjacent
organs or metastasis to para-aortic lymph nodes received benefit from neoadjuvant
chemotherapy. Based on these results and reports that bevacizumab enhances response rate, we
planned docetaxel, capecitabine, cisplatin, and bevacizumab as neoadjuvant chemotherapy for
patients with local invasion or para-aortic node metastasis alone.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
R0 resection rate
R0 resection means complete resection of tumor.
Up to 4 weeks after surgery
Min-Hee Ryu, MD, PhD
Asan Medical Center
Korea: Food and Drug Administration